Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF FGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2021/089005
Kind Code:
A1
Abstract:
Provided is the use of an FGFR inhibitor. More specifically, provided are an FGFR inhibitor for treating FGFR-related tumors or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, a method for treating FGFR-related tumors by means of using a drug comprising same, and the use thereof in the preparation of a drug for treating FGFR-related tumors. In vitro and in vivo test results show that compound A has the effect of inhibiting the activity of digestive or urinary system tumors related to abnormal FGFR expression, can be used to develop a drug for treating diseases involving digestive or urinary system tumors, and has important clinical application values.

Inventors:
WANG CAIXIA (CN)
WANG LINGLING (CN)
ZHANG YANG (CN)
LI GUIXIA (CN)
QI HUANHUAN (CN)
ZHAO JING (CN)
LI XIAO (CN)
Application Number:
PCT/CN2020/127211
Publication Date:
May 14, 2021
Filing Date:
November 06, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
International Classes:
A61K31/53; A61P35/00
Domestic Patent References:
WO2020164603A12020-08-20
WO2019034076A12019-02-21
WO2019034075A12019-02-21
WO2017215485A12017-12-21
WO2018121650A12018-07-05
Foreign References:
CN104245700A2014-12-24
CN103958512A2014-07-30
Other References:
GAIA CRISTINA GHEDINI; ROBERTO RONCA; MARCO PRESTA; ARIANNA GIACOMINI: "Future applications of FGF/FGFR inhibitors in cancer", EXPERT REVIEW OF ANTICANCER THERAPY, vol. 18, no. 9, 1 January 2018 (2018-01-01), GB, pages 861 - 872, XP009527867, ISSN: 1473-7140, DOI: 10.1080/14737140.2018.1491795
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF: